CTI Clinical Trial and Consulting Services Announces Acquisition of CRS Clinical Research Services
Cincinnati, Ohio
CTI Clinical Trial and Consulting Services (CTI) announces the acquisition of CRS Clinical Research Services and CRS – Staff Leasing Services (CRS), a clinical research organization headquartered in Northern Germany. CTI will incorporate all CRS employees into its current European operations and maintain the CRS headquarters located near Hamburg, Germany. CTI is planning to augment its coverage in Germany with the opening of an additional office in the southern region of the country in the coming months.
CRS is a full service, therapeutically-focused clinical research organization, with an emphasis on phase II and phase III clinical trials. Therapeutic areas of focus include infectious disease, oncology, and autoimmune diseases. CRS has managed clinical trials for large pharmaceutical companies, biotechnology companies, and for non-profit organizations across Western Europe.
“The addition of the CRS management and research teams will significantly advance CTI’s current expansion in Europe,” says Timothy Schroeder, CTI President and CEO.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
